Ballew Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Ballew Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5	Closed	–	–	105
2018 Q3	$0	Buy	+5	New	+$89	﹤0.01%	483

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ballew Advisors's AMPH Position: Q4 2018 in Review

Ballew Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2018, closing a stake of 5 shares.

Ballew Advisors first reported a position in AMPH in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 134 funds tracked by Wall St. Rank hold AMPH as of Q4 2018.

Ballew Advisors reported no remaining Amphastar Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 5 Amphastar Pharmaceuticals shares in Q4 2018.
Ballew Advisors first reported a position in Amphastar Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Amphastar Pharmaceuticals position peaked at $0 in Q3 2018.
134 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.